NCT05688215
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Locations
-
- Yonemoto,Lisa Los Angeles, California, United States
Clinical trial condition
Borderline Resectable Pancreatic Adenocarcinoma
Explore clinical trials studying Borderline Resectable Pancreatic Adenocarcinoma. Study availability and eligibility vary by location and protocol.
17 public trials
8 recruiting studies
Borderline Resectable Pancreatic Adenocarcinoma trial results
NCT06673017
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +9 more
- Locations
-
- Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
- Karmanos Cancer Institute Detroit, Michigan, United States
- Northwell Health Zuckerberg Cancer Center Lake Success, New York, United States
- University of Texas Southwestern Medical Center Dallas, Texas, United States
Recruiting
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05825066
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreas Adenocarcinoma
- Locations
-
- Wake Forest Baptist Comprehensive Cancer Center Winston-Salem, North Carolina, United States
NCT06384560
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Locations
-
- Amsterdam University Medical Center Amsterdam, Netherlands
- Maastricht University Medical Center Maastricht, Netherlands
- St. Antonius Ziekenhuis Nieuwegein, Netherlands
- Erasmus University Medical Center Rotterdam, Netherlands
Recruiting
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
NCT07240766
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Locations
-
- First Affiliated Hospital of Zhejiang University Schlool of Medicine Hangzhou, Zhejiang, China
- the First Affiliated Hospital of Zhejiang University, School of Medicine Hangzhou, Zhejiang, China
NCT07080021
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Locations
-
- Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai, China
- Ruijin hospital Shanghai, China
NCT05083247
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +8 more
- Locations
-
- Uza Antwerp Antwerp, Belgium
- Hopital Erasme, HUB Brussels, Belgium
- Jules Bordet Institute, HUB Brussels, Belgium
- CHIREC Brussels, Belgium
NCT05356039
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Chemotherapy Effect, Digestive System Diseases, +14 more
- Locations
-
- Surgical Clinic at Umeå University Hospital Umeå, Sweden
Not Yet Recruiting
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
NCT07415525
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +7 more
- Locations
-
- First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang Hangzhou, Zhejiang, China
NCT04669197
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Untreated Resectable Pancreatic Adenocarcinoma
- Locations
-
- HonorHealth Research Institute Scottsdale, Arizona, United States